Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly
Clinicians may review diabetes status, blood pressure, lipids, sleep apnea, liver health, pregnancy plans, eating-disorder history, and prior medication responses
The commercial success of GLP-1 receptor agonists such as Ozempic, Wegovy, and Rybelsus, along with dual GIP/GLP-1 receptor agonists including Mounjaro and Zepbound, has significantly increased the requirement for large-scale, high-quality peptide API manufacturing
Cuando se detallan lmites, comisiones y plazos, el usuario puede planificar sin sorpresas
It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors)
Puede tomarse solo, o ser mezclado con agua o jugo
US$ 27.52
US$ 29.48
US$ 20.09
US$ 27.74
US$ 29.74
US$ 23.82
